vrdn-003
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
5
Phase 4
0
Earliest trial started Aug 27, 2024 (NCT06625411)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
IGF1R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07211776 | Phase 3 | Dec 27, 2025 | Zai Lab Pty. Ltd. |
| NCT07155668 | Phase 3 | Jul 1, 2025 | Viridian Therapeutics |
| NCT06812325 | Phase 3 | Feb 28, 2025 | Viridian Therapeutics |
| NCT06625398 | Phase 3 | Aug 27, 2024 | Viridian Therapeutics |
| NCT06625411 | Phase 3 | Aug 27, 2024 | Viridian Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Viridian Therapeutics | For profit | 4 | 4 | 1 | 2024 |
| Zai Lab Pty. Ltd. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1